Resistance against PSMA-targeting alpha-radiation therapy coincides with mutations in DNA-repair associated genes

2019 ◽  
Author(s):  
C Kratochwil ◽  
CP Heussel ◽  
F Bruchertseifer ◽  
U Haberkorn ◽  
A Morgenstern ◽  
...  
2015 ◽  
Vol 17 (suppl 3) ◽  
pp. iii37-iii37
Author(s):  
F. Kievit ◽  
Z. Stephen ◽  
K. Wang ◽  
C. Dayringer ◽  
J. Silber ◽  
...  

2018 ◽  
Vol 127 ◽  
pp. S192-S193
Author(s):  
D. Yu ◽  
W. Daddacha ◽  
A. Koyen ◽  
A. Bastien ◽  
P. Head ◽  
...  

2014 ◽  
Vol 16 (suppl 5) ◽  
pp. v162-v162
Author(s):  
F. Kievit ◽  
Z. Stephen ◽  
K. Wang ◽  
C. Dayringer ◽  
R. Ellenbogen ◽  
...  

2019 ◽  
Vol 5 (suppl) ◽  
pp. 130-130 ◽  
Author(s):  
Jason Joon Bock Lee ◽  
Andrew Jihoon Yang ◽  
Jee Suk Chang ◽  
Han Sang Kim ◽  
Hong In Yoon ◽  
...  

130 Background: Somatic mutations of genes involved in DNA repair (e.g. ATM and BRCA1/2) may result in chemotherapy resistance and poor prognosis, but may confer sensitivity to radiation therapy. In this study, we aimed to the hypothesis that patients with such mutations may be more susceptible to radiotherapy. Methods: Using prospectively collected RT registry, we identified patients who underwent both RT to gross disease and NGS panel screening between 2013 and 2019 (N = 27,664). From a cohort of 134 patients, 33 patients with somatic mutation in ATM or BRCA 1/2 were identified and closely matched with 33 patients without mutation using propensity score based on radiation dose and histology. Results: Infield response rate was evaluated in 66 patients with 90 gross lesions (ATM mutation, 11 patients and BRCA 1/2 mutation, 22 patients). The median tumor size and RT dose was 24 mm (3-140) and 40 Gy (12-66), respectively. Stark differences were seen in infield complete response rate, overall response rate, and local control rate at target lesions by ATM mutation (mutation vs. no mutation; 50% vs. 8%, 61% vs. 24%, and 94% vs. 58%, P < .05). Response duration was also longer ATM mutation (median 11 vs. 3 months, P = .001). However, RT-related toxicities were not different (17% vs. 11%, P = .515) and no severe toxicity occurred. Conclusions: ATM mutations confer exceptional responses to radiation therapy, even with palliative dose, which has potential therapeutic implications.


2020 ◽  
Vol 22 (10) ◽  
pp. 1276-1285
Author(s):  
Yanke Chen ◽  
Ting Jiang ◽  
Hongyi Zhang ◽  
Xingchun Gou ◽  
Cong Han ◽  
...  

2016 ◽  
Vol 32 ◽  
pp. 115
Author(s):  
F. Zenone ◽  
C. Gasperi ◽  
A. Baldoncini ◽  
G. Belli

2016 ◽  
Vol 96 (2) ◽  
pp. E566-E567
Author(s):  
B. Marples ◽  
S.A. Krueger ◽  
T.G. Wilson ◽  
M.B. Dabjan ◽  
K.C. Lee ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Angeles Carlos-Reyes ◽  
Marcos A. Muñiz-Lino ◽  
Susana Romero-Garcia ◽  
César López-Camarillo ◽  
Olga N. Hernández-de la Cruz

Radiation therapy has been used worldwide for many decades as a therapeutic regimen for the treatment of different types of cancer. Just over 50% of cancer patients are treated with radiotherapy alone or with other types of antitumor therapy. Radiation can induce different types of cell damage: directly, it can induce DNA single- and double-strand breaks; indirectly, it can induce the formation of free radicals, which can interact with different components of cells, including the genome, promoting structural alterations. During treatment, radiosensitive tumor cells decrease their rate of cell proliferation through cell cycle arrest stimulated by DNA damage. Then, DNA repair mechanisms are turned on to alleviate the damage, but cell death mechanisms are activated if damage persists and cannot be repaired. Interestingly, some cells can evade apoptosis because genome damage triggers the cellular overactivation of some DNA repair pathways. Additionally, some surviving cells exposed to radiation may have alterations in the expression of tumor suppressor genes and oncogenes, enhancing different hallmarks of cancer, such as migration, invasion, and metastasis. The activation of these genetic pathways and other epigenetic and structural cellular changes in the irradiated cells and extracellular factors, such as the tumor microenvironment, is crucial in developing tumor radioresistance. The tumor microenvironment is largely responsible for the poor efficacy of antitumor therapy, tumor relapse, and poor prognosis observed in some patients. In this review, we describe strategies that tumor cells use to respond to radiation stress, adapt, and proliferate after radiotherapy, promoting the appearance of tumor radioresistance. Also, we discuss the clinical impact of radioresistance in patient outcomes. Knowledge of such cellular strategies could help the development of new clinical interventions, increasing the radiosensitization of tumor cells, improving the effectiveness of these therapies, and increasing the survival of patients.


Sign in / Sign up

Export Citation Format

Share Document